Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Omeros is a clinical-stage biopharmaceutical company focused on inflammation and central nervous system (CNS) disorders. Its primary platform, PharmacoSurgery, delivers low-dose combinations of therapeutic agents directly to surgical sites to inhibit inflammation and pain. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | 2009 | 2008 | 2007 |
|---|---|---|---|
| Grant Revenue | $1.4 million | $1.2 million | $1.9 million |
| Research & Development Expenses | $16.9 million | $17.9 million | $15.9 million |
| General & Administrative Expenses | $5.3 million | $7.8 million | $10.4 million |
| Net Loss | $(21.1) million | $(23.8) million | $(23.1) million |
| Cash, Cash Equivalents & Short-Term Investments | $60.3 million | $20.0 million | $24.1 million |
| Total Notes Payable | $12.8 million | $16.7 million | $1.0 million |
| Accumulated Deficit | $(118.3) million | $(97.2) million | $(73.4) million |
Note: Revenue consists entirely of grant funding from third parties (e.g., NIH, Stanley Medical Research Institute, Michael J. Fox Foundation). The company completed its Initial Public Offering (IPO) in October 2009, raising approximately $61.8 million in net proceeds.
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and short-term investments increased significantly from $20.0 million in 2008 to $60.3 million in 2009, primarily due to the October 2009 IPO.
- Debt Structure: The company borrowed $17.0 million in 2008 under a loan agreement with BlueCrest Venture Finance Master Fund Limited. As of December 31, 2009, the outstanding principal was approximately $12.8 million. The company paid a $340,000 success fee to BlueCrest upon the IPO.
- Expense Reduction: General and Administrative expenses decreased by approximately $2.5 million compared to 2008, largely due to the write-off of $1.9 million in deferred offering costs in 2008 and lower stock-based compensation in 2009.
- Equity Position: Total shareholders' equity turned positive ($43.1 million) in 2009 from a deficit of $(91.2) million in 2008, driven by the conversion of preferred stock and IPO proceeds.
Guidance, Outlook, and Risks
Outlook and Milestones
- OMS103HP (Lead Candidate): Phase 3 clinical trials for ACL reconstruction surgery are ongoing. Results are expected in the second half of 2010. If approved, the company anticipates market entry no earlier than 2011.
- OMS302 (Ophthalmology): Preparing to initiate a second Phase 2 clinical trial for cataract surgery in mid-2010.
- OMS201 (Urology): Phase 1/Phase 2 trial for ureteroscopy is underway, with completion expected in mid-2010.
- Addiction Program: The National Institute on Drug Abuse agreed to fund a Phase 2 study for opioid addiction, with enrollment expected in the first half of 2010.
Management Commentary
Management expects net losses to increase in the near term as the company advances clinical trials, expands R&D, and adds personnel. The company believes its existing cash resources are sufficient to fund operations for at least the next 12 months.
Risks and Contingencies
- Regulatory Risk: The FDA has questioned the study design for OMS103HP and the demonstration of contribution for each active ingredient in the combination drug. Additional studies may be required.
- Capital Requirements: The company has no commitments for future funding. If additional capital is needed, it may be raised through equity (causing dilution) or debt (restricting operations).
- Debt Covenants: The BlueCrest loan agreement contains a "material adverse effect" clause that could trigger immediate repayment if the company's viability is threatened.
- Legal Proceedings: The former CFO, Richard J. Klein, filed a lawsuit alleging wrongful termination and violations of the False Claims Act. The company intends to defend vigorously.
Investor Verification Checklist
- Cash Runway: Verify if the $60.3 million cash balance is sufficient to fund the Phase 3 OMS103HP trials and other programs through 2011 without additional financing.
- Debt Terms: Review the specific triggers for the "material adverse effect" clause in the BlueCrest loan agreement and the impact of the 12.5% interest rate on future cash flows.
- Regulatory Status: Monitor FDA communications regarding the OMS103HP Phase 3 trial design and the requirement to prove the efficacy of each individual API in the combination.
- Intellectual Property: Confirm the status of the exclusive license option with Patobios Limited for the GPCR program, which could require a purchase price of approximately $10.8 million CAD.
- Legal Exposure: Track the progress of the lawsuit filed by the former CFO and any potential financial impact.